hepatomiR cACLD Study

Recruiting now

Conditions studied: Chronic Liver Disease and Cirrhosis, Chronic Liver Disease, Portal Hypertension

In brief

This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.

Key facts

Study ID

NCT06432582

Run by

Karl Landsteiner University of Health Sciences

People needed

156

Starts

2024-05-15

Expected to finish

2026-06-01

Last updated by the study team

2025-09-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Chronic liver disease (more than 6 months)
• LSM ≥ 10 kPa
• Outpatient at the Clinical Department of Internal Medicine II, University Hospital St. Pölten
• Signed patient consent form

You may not qualify if…

• Age older than 18 years
• Pregnancy
• Primary hepatic malignancy (hepatocellular carcinoma, cholangiocarcinoma) with portal invasion and/or extrahepatic spread

Where it is running

• University Hospital St. Pölten — Sankt Pölten, Lower Austria, Austria (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.